Biomarin Pharmaceutical Inc revenue
Biomarin Pharmaceutical Inc's revenue was $3.22bn in fiscal 2025, up 12.9% on the year before. Since fiscal 2009 ($325m) it has grown at a compound 15.4% a year. Over the last twelve months it was $3.41bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 325 | 376 | 441 | 501 | 548 | 749 | 890 | 1,117 | 1,314 | 1,491 | 1,704 | 1,860 | 1,846 | 2,096 | 2,419 | 2,854 | 3,221 | 3,407 |
| Growth on the year before | — | +15.9% | +17.3% | +13.5% | +9.5% | +36.6% | +18.8% | +25.5% | +17.6% | +13.5% | +14.3% | +9.2% | −0.8% | +13.5% | +15.4% | +18.0% | +12.9% | — |
| Gross profit | 259 | 306 | 357 | 409 | 460 | 627 | 738 | 907 | 1,072 | 1,176 | 1,345 | 1,336 | 1,376 | 1,593 | 1,887 | 2,274 | 2,504 | 2,593 |
| Gross margin | 79.7% | 81.3% | 81.0% | 81.7% | 83.9% | 83.7% | 82.9% | 81.2% | 81.6% | 78.9% | 78.9% | 71.8% | 74.5% | 76.0% | 78.0% | 79.7% | 77.7% | 76.1% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $3.2B | 98.3% | ▲ 12.8% |
| VOXZOGO (part of Products) | $927M | 29.3% | ▲ 26.1% |
| VIMIZIM (part of Products) | $792M | 25.0% | ▲ 7.1% |
| NAGLAZYME (part of Products) | $485M | 15.3% | ▲ 1.2% |
| PALYNZIQ (part of Products) | $433M | 13.7% | ▲ 22.0% |
| ALDURAZYME (part of Products) | $209M | 6.6% | ▲ 13.4% |
| BRINEURA (part of Products) | $186M | 5.9% | ▲ 10.2% |
| KUVAN (part of Products) | $99.5M | 3.1% | ▼ 17.7% |
| ROCTAVIAN (part of Products) | $35.6M | 1.1% | ▲ 36.7% |
| Royalty and Other | $53.5M | 1.7% | ▲ 20.3% |
From Biomarin Pharmaceutical Inc's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Biomarin Pharmaceutical Inc | $3.41bn | 11.2% | 15.1% |
| Biontech SE | $3.24bn | 9.0% | — |
| United Therapeutics Corp | $3.15bn | 2.5% | 14.3% |
| Neurocrine Biosciences Inc | $3.70bn | 38.0% | 27.5% |
| Argenx SE | $4.15bn | 89.9% | — |
| Natera, Inc. | $2.71bn | 37.8% | 42.7% |
Compare with peers
- Biontech SE revenue
- United Therapeutics Corp revenue
- Neurocrine Biosciences Inc revenue
- Argenx SE revenue
- Natera, Inc. revenue
Head to head: BMRN vs BNTXBMRN vs UTHRBMRN vs NBIXARGX vs BMRN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies